Aeglea BioTherapeutics Inc
NASDAQ:AGLE
| Market Cap (Intraday) | 391.80M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $8.05 |
| 50-Day MA | $7.34 |
| 200-Day MA | $7.35 |
Aeglea BioTherapeutics Inc Stock, NASDAQ:AGLE
805 Las Cimas Parkway, Suite 100, Austin, Texas 78746
United States of America
Phone: +1.512.942.2935
Number of Employees: 90
Description
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.